NVS Stock Recent News

The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, defensive ones, offer a stable investment strategy during trade war turmoil. They provide dependable income and lower downside risk. The recommended 10 low volatility dividend aristocrats include Johnson & Johnson, PepsiCo, and Kimberly-Clark, offering a 4% yield and strong long-term return potential.

Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's Chairman Joerg Reinhardt said in an interview published on Thursday.

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.

It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III REMIX pivotal trials of investigational remibrutinib, demonstrating impact in key clinical outcomes for patients with CSU also to be presented Regulatory submissions for remibrutinib as a treatment for CSU on track for filing in 1H 2025   EAST HANOVER, N.J. , Feb. 28, 2025 /PRNewswire/ -- Novartis announced today it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Basel, February 28, 2025 – Novartis announced today it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Basel, February 28, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Fabhalta ®  (iptacopan) – a first-in-class oral Factor B inhibitor of the alternative complement pathway – for the treatment of adults with C3 glomerulopathy (C3G)1.

At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So, sales of Pluvicto, a medication for the treatment of prostate cancer, reached $351 million in the fourth quarter of 2024, an increase of 28.6% year-on-year. Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector.

Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost development of biologic crop protection.